GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection
European Respiratory Journal · 2023
DOI: 10.1183/13993003.01306-2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Cheng Xiang Foo und 21 weiteren Autor:innen. Beteiligte Einrichtung: Mater Research Institute, Translational Research Institute, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Influenza, Human, COVID-19. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, Australian Infectious Diseases Research Centre, Australian Respiratory Council.
Abstract (Originalsprache)
Rationale
Severe viral respiratory infections are often characterised by extensive myeloid cell infiltration and activation and persistent lung tissue injury. However, the immunological mechanisms driving excessive inflammation in the lung remain poorly understood.
Objectives
To identify the mechanisms that drive immune cell recruitment in the lung during viral respiratory infections and identify novel drug targets to reduce inflammation and disease severity.
Methods
Preclinical murine models of influenza A virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Results
Oxidised cholesterols and the oxysterol-sensing receptor GPR183 were identified as drivers of monocyte/macrophage infiltration to the lung during influenza A virus (IAV) and SARS-CoV-2 infection. Both IAV and SARS-CoV-2 infection upregulated the enzymes cholesterol 25-hydroxylase (CH25H) and cytochrome P450 family 7 subfamily member B1 (CYP7B1) in the lung, resulting in local production of the oxidised cholesterols 25-hydroxycholesterol (25-OHC) and 7α,25-dihydroxycholesterol (7α,25-OHC). Loss-of-function mutation of Gpr183 or treatment with a GPR183 antagonist reduced macrophage infiltration and inflammatory cytokine production in the lungs of IAV- or SARS-CoV-2-infected mice. The GPR183 antagonist significantly attenuated the severity of SARS-CoV-2 infection and viral loads. Analysis of single-cell RNA-sequencing data on bronchoalveolar lavage samples from healthy controls and COVID-19 patients with moderate and severe disease revealed that CH25H , CYP7B1 and GPR183 are significantly upregulated in macrophages during COVID-19.
Conclusion
This study demonstrates that oxysterols drive inflammation in the lung via GPR183 and provides the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mater Research Institute, Translational Research Institute, The University of Queensland, Brisbane, Australia.
- Contributed equally to this work.
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
- Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Australia.
- Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
- Institute for Molecular Bioscience (IMB), IMB Centre for Inflammation and Disease Research, The University of Queensland, Brisbane, Australia.
ORCID-Profile: Cheng Xiang Foo, Christian Smith, Katharina Ronacher
Förderung
- NIAID NIH HHS
- Australian Infectious Diseases Research Centre
- Australian Respiratory Council
- Danmarks Frie Forskningsfond
- Diabetes Australia
- Mater Foundation
- National Health and Medical Research Council
Zitieren
APA
Foo, C. X., Bartlett, S., Chew, K. Y., Ngo, M. D., Bielefeldt-Ohmann, H., Arachchige, B. J., Matthews, B., Reed, S., Wang, R., Smith, C., Sweet, M. J., Burr, L., Bisht, K., Shatunova, S., Sinclair, J. E., Parry, R., Yang, Y., Lévesque, J. P., Khromykh, A., …, & Ronacher, K. (2023). GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. European Respiratory Journal. https://doi.org/10.1183/13993003.01306-2022
Vancouver
Foo CX, Bartlett S, Chew KY, Ngo MD, Bielefeldt-Ohmann H, Arachchige BJ, et al. GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. European Respiratory Journal. 2023. doi:10.1183/13993003.01306-2022
BibTeX
@article{Foo2023,
author = {Foo, Cheng Xiang and Bartlett, Stacey and Chew, Keng Yih and Ngo, Minh Dao and Bielefeldt-Ohmann, Helle and Arachchige, Buddhika Jayakody and Matthews, Benjamin and Reed, Sarah and Wang, Ran and Smith, Christian and Sweet, Matthew J and Burr, Lucy and Bisht, Kavita and Shatunova, Svetlana and Sinclair, Jane E and Parry, Rhys and Yang, Yuanhao and Lévesque, Jean-Pierre and Khromykh, Alexander and Rosenkilde, Mette Marie and Short, Kirsty R and Ronacher, Katharina},
title = {GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection},
journal = {European Respiratory Journal},
year = {2023},
doi = {10.1183/13993003.01306-2022}
}
EUVIMED